KH-200

KH-200 is a small molecule inhibitor of the RNA-binding protein HuR (ELAV-like protein 1, encoded by the ELAVL1 gene), developed by researchers at the University of Kansas. HuR is a member of the embryonic lethal abnormal vision (ELAV) family that is overexpressed in various cancers and promotes tumorigenesis by stabilizing oncogenic mRNAs, including PD-L1. KH-200 acts by disrupting the translocation of HuR from the nucleus to the cytoplasm. In preclinical studies, KH-200 has been evaluated in combination with anti-PD-1 immunotherapy, demonstrating significant tumor growth inhibition and prolonged survival in syngeneic mouse models of breast cancer (EMT6) and lung cancer (Lewis lung).